-
[show abstract]
[hide abstract]
ABSTRACT: Diagnosis and follow-up of bone metastasis (BMet) in non-small cell lung cancer (NSCLC) patients usually rely on symptoms and image studies. A serum marker of bone resorption may improve the quality of treatment in such patients. Tartrate-resistant acid phosphatase 5b (TRACP5b) is a specific marker for osteoclasts and we proposed it can be used as a marker of BMet in NSCLC patients.
In November 2002 till August 2008 serum samples were obtained from 141 newly diagnosed stage IIIA, IIIB or IV NSCLC patients and 41 normal subjects. All patients received baseline bone scintinography examination and evaluation of clinical symptoms as a standard of BMet diagnosis. Patients were divided into 2 groups by having BMet (Group I, n = 72) or not (Group II, n = 69). An in-house immunoassay using a TRACP-specific monoclonal antibody, 14G6, was used to measure the serum TRACP5b activity at pH 6.1.
The mean serum TRACP5b activities of Group I, Group II and normal subjects were 3.50 ± 2.2 3U/l, 2.09 ± 0.72 U/l and 2.33 ± 0.52 U/l, respectively. After adjusting for age, stage, gender, and histology in a generalized linear model, Group I has significantly higher TRACP5b activity than Group II (p < 0.001). The receiver operating characteristic analysis established a cutoff value of 2.551 U/l to identify BMet in NSCLC patients with a sensitivity of 63.9% and a specificity of 76.8%. TRACP5b activity declined in patients who responded to treatment (p = 0.047), and elevated in patients who developed new BMet (p = 0.05).
Serum TRACP5b activity test is a potentially useful adjunct in diagnosing and monitoring BMet in NSCLC. Further study is warranted to establish its real value in diagnosis and monitoring of BMet in NSCLC patients.
Clinica chimica acta; international journal of clinical chemistry 10/2010; 412(1-2):181-5. · 2.54 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Cetuximab has been proved to be effective alone or in combination with other chemotherapeutic agents in the treatment of various malignancies. The aim of this report was to describe our experience of using cetuximab with chemotherapeutics agents to treat advanced-stage biliary tract cancer.
We retrospectively analyzed the outcomes of 5 biliary tract cancer patients receiving cetuximab-containing therapy. Four of them had stage IV disease, and 1 patient had incomplete resection at the time of diagnosis. Epidermal growth factor receptor (EGFR) expression and K-ras status were assessed when a specimen was available. After cetuximab treatment, complete response was achieved in 1 patient, partial response in 3 patients, and stable disease in 1 patient. Three surgical specimens were available, and all revealed positive EGFR expression. Only 1 surgical specimen was adequate for K-ras mutation test, and the wild type was confirmed. Complete response was found in the patient who had wild type K-ras. The progression-free survival of these patients varied from 4 to 16 months.
Cetuximab-containing therapy might be an effective treatment for advanced biliary tract cancer.
Onkologie 01/2010; 33(1-2):45-7. · 0.87 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Distant metastasis from lung cancer occurs most frequently to the brain, bone, adrenal gland, liver, lymph nodes, and spinal cord. However, masticator space metastasis is rarely found among lung cancer patients.
We report a case of large cell neuroendocrine carcinoma of the lung with metastasis to the masticator space diagnosed by imaging and histopathological examinations.
The present case highlights the fact that large cell neuroendocrine carcinoma of the lung can result in an uncommon isolated masticator space metastasis. Clinicians should carefully evaluate cancer patients who report a painful sensation in the cheek. Thorough dental and physical examination, and imaging studies could provide early diagnosis and treatment.
Onkologie 07/2009; 32(6):349-51. · 0.87 Impact Factor
-
Journal of Clinical Oncology 06/2009; 27(23):e48. · 18.37 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Germ cell tumors (GCT) are the most common malignancies among male adolescents. Approximately 5% of GCTs are of extragonadal origin. Cisplatin-based chemotherapy is the standard first-line treatment for GCT. Patients who fail to respond to first-line treatment usually have poor outcomes. High-dose chemotherapy with stem cell support, paclitaxel, gemcitabine, and oxaliplatin are reported as effective salvage treatment. We report two patients with cisplatin-refractory, metastatic, nonseminomatous, and extragonadal GCT treated successfully with gemcitabine plus vinorelbine (GV). One patient achieved good partial remission and had a five-month progression-free period. Another patient is still alive with stable disease after 4 cycles of treatment. In heavily treated, cisplatin-refractory GCT patients, GV could be considered an effective chemotherapeutic regimen.
Southern medical journal 05/2009; 102(5):546-8. · 0.92 Impact Factor
-
Annals of Hematology 04/2009; 88(12):1257-9. · 2.62 Impact Factor
-
Hematology/ Oncology and Stem Cell Therapy 01/2009; 2(2):371-2.
-
[show abstract]
[hide abstract]
ABSTRACT: Although ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) is a well-known paraneoplastic phenomenon, an association with large-cell neuroendocrine carcinoma of the lung (LCNEC) has not been reported. We describe a 63-year-old man with metastatic LCNEC to the left temporomandibular joint (TMJ) who presented with progressive muscle weakness and bilateral lower leg edema for 2 weeks. He did not have a typical Cushingoid appearance nor used diuretics. His newly noted hypertension, hypokalemia (plasma potassium (K) concentration 1.8 mEq/L) with renal K wasting, and metabolic alkalosis suggested a state of mineralocorticoid excess. His plasma renin activity and aldosterone concentrations were low, but cortisol and ACTH levels were extremely elevated, consistent with ACTH-dependent Cushing's syndrome. Nonsuppressible plasma cortisol level and normal sella turcica on magnetic resonance imaging pointed to EAS. A strongly positive stain for ACTH from the metastatic left TMJ mass supported LCNEC-related EAS. His hypokalemia and hypertension were controlled with spironolactone and K supplementation. This is the first reported case of EAS in LCNEC and should be kept in mind as a cause of hypokalemia in lung cancer patients.
The American Journal of the Medical Sciences 01/2008; 334(6):487-9. · 1.39 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Ectopic hepatocellular carcinoma (HCC) is very rarely reported. It may occur at various sites. To the best of our knowledge, only one case of ectopic HCC of the diaphragm has been reported. We present another such case with invasion to the lung. Subtotal resection of the left hemidiaphragm, wedge resection of the lung (left lower lobe), and splenectomy were undertaken. Postoperative course was unremarkable; the patient received two courses of adjuvant chemotherapy with cisplatin, VP-16, and bleomycin 1 month later. Follow-up computed tomography and ultrasound were performed 8 months later; there was no local recurrence or distal metastasis.
Digestive Diseases and Sciences 05/2007; 52(4):1118-20. · 2.12 Impact Factor
-
Annals of Hematology 11/2005; 84(11):764-6. · 2.62 Impact Factor
-
Po-Min Chen, Nai-Shun Yao,
Ching-Mei Wu,
Muh-Hwa Yang,
Yu-Chen Lin,
Liang-Tsai Hsiao,
Chueh-Chuan Yen,
Wei-Shu Wang,
Frank S. Fan,
Tzeon-Jye Chiou,
Jin-Hwang Liu,
Szecheng J. Lo
[show abstract]
[hide abstract]
ABSTRACT: Background. This study elucidates the profiles for hepatitis B virus (HBV) reactivation and genetic mutation of the core promoter and precore regions for HBV-carriers receiving hematopoietic stem cell transplantation (HSCT).
Methods. Sera from 20 HSCT patients diagnosed with hematological diseases, 13 donors and 36 healthy HBV-carriers, were collected regularly for analysis. The hepatic biochemistry profiles, serological HBV markers, and HBV-DNA titers were checked regularly, and primer-amplification of the HBV core promoter or precore region and sequencing were performed once the mutations were identified.
Results. Deteriorated liver function was demonstrated for 13 of 20 post-HSCT patients, compared with none of the 36 controls (P <0.01). The HBV-DNA was detected more frequently for post-HSCT subjects than for controls (P =0.001). Incidence of the HBV precore nucleotide 1896 G-to-A mutation was significantly higher for HSCT patients (P =0.004), and a significant association was demonstrated for carriage of core promoter or precore mutations and the development of hepatitis (P =0.015). Different HBV genotypes were revealed in post-HSCT patients and the respective donors.
Conclusions. Intensive chemotherapy and immunosuppression may cause HBV reactivation in HBV carriers receiving HSCT, and more frequent core promoter or precore mutations could be detected in HBV carriers receiving HSCT than healthy HBV carriers, with the chemotherapy/immunosuppression-induced immunocompromise possibly contributing to this effect. Donor HBV genotype did not interfere with that of the recipient after HSCT. Core promoter or precore region mutations were associated with a higher incidence of liver dysfunction than wild-type HBV carriers in the HSCT patients.
Transplantation 07/2002; 74(2):182-188. · 4.00 Impact Factor
-
Po-Min Chen, Nai-Shun Yao,
Ching-Mei Wu,
Muh-Hwa Yang,
Yu-Chen Lin,
Liang-Tsai Hsiao,
Chueh-Chuan Yen,
Wei-Shu Wang,
Frank S Fan,
Tzeon-Jye Chiou,
Jin-Hwang Liu,
Szecheng J Lo
[show abstract]
[hide abstract]
ABSTRACT: This study elucidates the profiles for hepatitis B virus (HBV) reactivation and genetic mutation of the core promoter and precore regions for HBV-carriers receiving hematopoietic stem cell transplantation (HSCT).
Sera from 20 HSCT patients diagnosed with hematological diseases, 13 donors and 36 healthy HBV-carriers, were collected regularly for analysis. The hepatic biochemistry profiles, serological HBV markers, and HBV-DNA titers were checked regularly, and primer-amplification of the HBV core promoter or precore region and sequencing were performed once the mutations were identified.
Deteriorated liver function was demonstrated for 13 of 20 post-HSCT patients, compared with none of the 36 controls (P<0.01). The HBV-DNA was detected more frequently for post-HSCT subjects than for controls (P=0.001). Incidence of the HBV precore nucleotide 1896 G-to-A mutation was significantly higher for HSCT patients (P=0.004), and a significant association was demonstrated for carriage of core promoter or precore mutations and the development of hepatitis (P=0.015). Different HBV genotypes were revealed in post-HSCT patients and the respective donors.
Intensive chemotherapy and immunosuppression may cause HBV reactivation in HBV carriers receiving HSCT, and more frequent core promoter or precore mutations could be detected in HBV carriers receiving HSCT than healthy HBV carriers, with the chemotherapy/immunosuppression-induced immunocompromise possibly contributing to this effect. Donor HBV genotype did not interfere with that of the recipient after HSCT. Core promoter or precore region mutations were associated with a higher incidence of liver dysfunction than wild-type HBV carriers in the HSCT patients.
Transplantation 07/2002; 74(2):182-8. · 4.00 Impact Factor
-
Journal of Andrology 27(5):643-4. · 2.97 Impact Factor
